Question

Match each targeted anticancer drug with its molecular target. Which of the following pairings is entirely correct?

• A. Sunitinib - c-KIT/VEGFR; Nilotinib - BCR-ABL; Trastuzumab - HER2; Gefitinib - EGFR
• B. Sunitinib - HER2; Nilotinib - EGFR; Trastuzumab - BCR-ABL; Gefitinib - c-KIT
• C. Sunitinib - BCR-ABL; Nilotinib - c-KIT; Trastuzumab - EGFR; Gefitinib - HER2
• D. Sunitinib - EGFR; Nilotinib - HER2; Trastuzumab - c-KIT; Gefitinib - BCR-ABL

Hint:

Nilotinib treats CML; trastuzumab targets HER2 breast cancer.

Answer 1

The Correct Option is A

Step 1: Identify each drug's target.
Sunitinib is a multi-kinase tyrosine kinase inhibitor acting on VEGFR, PDGFR and c-KIT (used in renal cell carcinoma and imatinib-resistant GIST).
Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukaemia.
Trastuzumab is a monoclonal antibody against HER2 (ErbB2), used in HER2-positive breast and gastric cancer.
Gefitinib is an EGFR tyrosine kinase inhibitor for EGFR-mutant non-small-cell lung cancer.

Step 2: Match.
Sunitinib-c-KIT, Nilotinib-BCR-ABL, Trastuzumab-HER2, Gefitinib-EGFR. This is option 1.

Step 3: Reject the rest.
Every other option scrambles at least two targets, so only option 1 is fully correct.

Key fact: Sunitinib to c-KIT/VEGFR, Nilotinib to BCR-ABL, Trastuzumab to HER2, Gefitinib to EGFR.